Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | STP1002 |
Synonyms | |
Therapy Description |
STP1002 binds to and inhibits Tankyrase, which results in stabilization of AXIN and decreased Wnt/beta-catenin signaling, potentially leading to decreased cell proliferation and tumor growth (PMID: 35849876). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
STP1002 | STP 1002|STP-1002|basroparib | Tankyrase Inhibitor 11 | STP1002 binds to and inhibits Tankyrase, which results in stabilization of AXIN and decreased Wnt/beta-catenin signaling, potentially leading to decreased cell proliferation and tumor growth (PMID: 35849876). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
APC Q1338* | colorectal cancer | sensitive | STP1002 | Preclinical - Cell culture | Actionable | In a preclinical study, STP1002 inhibited Wnt/beta-catenin signaling and colony formation in colorectal cancer cell lines harboring APC Q1338* in culture (PMID: 35849876). | 35849876 |
APC E1309Dfs*4 | colorectal cancer | sensitive | STP1002 | Preclinical - Cell culture | Actionable | In a preclinical study, STP1002 inhibited Wnt/beta-catenin signaling and colony formation in a colorectal cancer cell line harboring APC E1309Dfs*4 in culture (PMID: 35849876). | 35849876 |
APC R1450* | colorectal cancer | sensitive | STP1002 | Preclinical - Pdx | Actionable | In a preclinical study, STP1002 inhibited tumor growth in a colorectal cancer patient-derived xenograft (PDX) model harboring APC R1450* (PMID: 35849876). | 35849876 |
APC E853* APC T1556Nfs*3 | colorectal cancer | sensitive | STP1002 | Preclinical - Cell culture | Actionable | In a preclinical study, STP1002 inhibited Wnt/beta-catenin signaling and colony formation in a colorectal cancer cell line harboring APC E853* and APC T1556Nfs*3 in culture (PMID: 35849876). | 35849876 |
APC S811* | colorectal cancer | sensitive | STP1002 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, STP1002 inhibited Wnt/beta-catenin signaling and colony formation in colorectal cancer cell lines harboring APC S811* in culture and inhibited tumor growth in a cell line xenograft model (PMID: 35849876). | 35849876 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04505839 | Phase I | STP1002 | First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors | Completed | USA | 0 |